open access

https://hdl.handle.net/2115/50792

Novel monoclonal antibody recognizing triglyceride-rich oxidized LDLs associated with severe liver disease and small oxidized LDLs in normal subjects

英語

2012-09

Royal Society of Medicine Press

Annals of Clinical Biochemistry

49(5)

456-462

Background: Triglyceride-rich low-density lipoproteins (TG-rich LDLs) in the plasma of patients with severe liver disease are reported to change macrophages into foam cells in vitro. Methods: Male BALB/c mice were immunized with TG-rich LDLs isolated from the plasma of a patient with severe liver disease. The resulting monoclonal antibody (G11-6) was used in a sandwich enzyme-linked immunosorbent assay (ELISA) in combination with polyclonal anti-apolipoprotein B antibodies. The time course of copper-mediated LDL oxidation was monitored using this ELISA. The results were compared to those of the two commercial ELISAs for oxidized LDL using DLH or ML25, thiobarbituric acid reactive substances (TBARS), and the optical absorbance for the conjugated dienes generated in lipid peroxides. Further, the lipoprotein fractions separated by gel filtration were tested with this ELISA in healthy volunteers (n = 11) and patients (n = 3) with liver disease. Results: G11-6 reacted with oxidized LDLs during only the early phase of copper-oxidation, being distinct from the other monoclonal antibodies and methods. G11-6 was confirmed to react with TG-rich LDLs in patients, while it reacted with small LDL particles in normal controls. Conclusions: The monoclonal antibody G11-6 is useful for detecting oxidized small LDLs in normal controls and oxidized TG-rich LDLs in patients with severe liver disease.

学術雑誌論文

Accepted Manuscript

Ann Clin Biochem, September 2012, vol. 49 no. 5, pp.456-462, doi: 10.1258/acb.2012.011284. This is the final draft, after peer-review, of a manuscript published in Annals of Clinical Biochemistry. The definitive version, detailed above, is available online at www.rsmjournals.com.

0004-5632